Using aspirin for coronary heart prevention
is less costly and more effective than doing nothing in men older than 45 with
more than 10 percent 10-year-risk of the disease, according to a study by
researchers at RTI International, University of Michigan, and University of
North Carolina at Chapel Hill.
The study, published online in the Archives of Internal Medicine, used a Markov model to compare the costs and outcomes of prescribing low-dose aspirin alone, aspirin plus a proton-pump inhibitor, or no treatment for coronary heart prevention. The researchers specifically considered the effects of each treatment on cardiovascular events and risk of upper gastrointestinal bleeding.
Seotud lood
Peagi, 6.märtsil peab oma 110. juubelit
valuvaigisti ja palavikuleevendaja Aspirin. Sellega seoses on ravimifirma Bayer
HealthCare võtnud auasjaks kummutada mõned aspiriini kohta käivad müüdid.
Meliva hambakliinikud Tallinnas, Sakus Pärnus ja Kuressaares ootavad oma kollektiivi hambaarste!